Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period.
Clinicaltrials.gov
clinical trial
immune checkpoint inhibitor
immunotherapy
nasopharyngeal carcinoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
03
2023
accepted:
24
07
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Immunotherapy has been a hotspot in nasopharyngeal carcinoma (NPC) in recent years. This study aimed to provide a comprehensive landscape of the characteristics of immunotherapy clinical trials in NPC and to determine whether contemporary studies are of sufficient quality to demonstrate therapeutic value. This is a cross-sectional analysis of NPC trials registered on ClinicalTrials.gov in the last 15 years (Jan 1, 2008-Nov 20, 2022). Only interventional trials with a primary purpose of treatment were included in the final analysis. Characteristics of immunotherapy trials were compared with those of other NPC trials. Chronological shifts in NPC immunotherapy trials were also analyzed. Of the 440 NPC studies selected, 161 (36.6%) were immunotherapy trials and 279 (63.4%) were other NPC trials. NPC immunotherapy trials were more likely than other NPC trials to be phase 1-2 (82.6% vs. 66.7%, NPC immunotherapy trials over a 15-year period were predominantly exploratory. To generate high-quality evidence and advance the clinical application of immunotherapy in NPC, more attention and concerted efforts are needed.
Sections du résumé
Background
Immunotherapy has been a hotspot in nasopharyngeal carcinoma (NPC) in recent years. This study aimed to provide a comprehensive landscape of the characteristics of immunotherapy clinical trials in NPC and to determine whether contemporary studies are of sufficient quality to demonstrate therapeutic value.
Methods
This is a cross-sectional analysis of NPC trials registered on ClinicalTrials.gov in the last 15 years (Jan 1, 2008-Nov 20, 2022). Only interventional trials with a primary purpose of treatment were included in the final analysis. Characteristics of immunotherapy trials were compared with those of other NPC trials. Chronological shifts in NPC immunotherapy trials were also analyzed.
Results
Of the 440 NPC studies selected, 161 (36.6%) were immunotherapy trials and 279 (63.4%) were other NPC trials. NPC immunotherapy trials were more likely than other NPC trials to be phase 1-2 (82.6% vs. 66.7%,
Conclusion
NPC immunotherapy trials over a 15-year period were predominantly exploratory. To generate high-quality evidence and advance the clinical application of immunotherapy in NPC, more attention and concerted efforts are needed.
Identifiants
pubmed: 37622113
doi: 10.3389/fimmu.2023.1195659
pmc: PMC10445486
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1195659Informations de copyright
Copyright © 2023 Huang, Yao, Deng, Weng, Chen, Yu, Wang, Fang, Hong, Huang and Lin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer YG declared a shared parent affiliation with the authors HGH, YY, HW, ZC, ZW, XF, HH, and TL to the handling editor at the time of review.
Références
Lancet Oncol. 2016 Jun;17(6):e254-e262
pubmed: 27299281
N Engl J Med. 2011 Mar 3;364(9):852-60
pubmed: 21366476
Cancer Treat Rev. 2018 Apr;65:54-64
pubmed: 29547766
Nat Med. 2021 Sep;27(9):1536-1543
pubmed: 34341578
Theranostics. 2017 Jan 1;7(2):390-399
pubmed: 28042342
Cancer Gene Ther. 2022 Jun;29(6):647-660
pubmed: 34158626
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Oral Oncol. 2018 Sep;84:61-70
pubmed: 30115477
Science. 2013 Dec 20;342(6165):1417
pubmed: 24357273
Lancet Oncol. 2021 Aug;22(8):1162-1174
pubmed: 34174189
Cancer Commun (Lond). 2021 May;41(5):361-370
pubmed: 33955719
Br J Cancer. 2017 Dec 5;117(12):1743-1752
pubmed: 29065104
NPJ Precis Oncol. 2021 Mar 19;5(1):24
pubmed: 33742086
J Exp Med. 2000 May 15;191(10):1649-60
pubmed: 10811859
JAMA Netw Open. 2021 May 3;4(5):e2110438
pubmed: 34028549
JAMA Oncol. 2018 Aug 1;4(8):1073-1079
pubmed: 29799987
JAMA. 2012 May 2;307(17):1838-47
pubmed: 22550198
Cancer Cell. 2023 Jan 9;41(1):58-69
pubmed: 36400016
J Clin Oncol. 2023 May 10;41(14):2571-2582
pubmed: 36735896
Blood. 2009 Jun 11;113(24):6148-52
pubmed: 19372256
Oncoimmunology. 2017 Jan 4;6(2):e1273311
pubmed: 28344888
Cell Res. 2020 Nov;30(11):1024-1042
pubmed: 32686767
Int J Cancer. 2021 Jul 1;149(1):108-118
pubmed: 33544890
Clin Cancer Res. 2021 Dec 1;27(23):6413-6423
pubmed: 34433653
Nat Rev Clin Oncol. 2021 Nov;18(11):679-695
pubmed: 34194007
Lancet Oncol. 2018 Oct;19(10):1338-1350
pubmed: 30213452
Lancet. 2004 Sep 11-17;364(9438):911-2
pubmed: 15364170
J Immunother. 2013 Apr;36(3):208-14
pubmed: 23502768
Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4
pubmed: 37207654
N Engl J Med. 2004 Sep 16;351(12):1250-1
pubmed: 15356289
J Clin Oncol. 2018 May 10;36(14):1412-1418
pubmed: 29584545
J Clin Oncol. 2021 Mar 1;39(7):704-712
pubmed: 33492986
Am J Pathol. 1995 Oct;147(4):1152-60
pubmed: 7573360
JAMA Intern Med. 2013 Jun 10;173(11):972-9
pubmed: 23699837
J Immunother Cancer. 2021 Dec;9(12):
pubmed: 34933967
J Clin Oncol. 2017 Dec 20;35(36):4050-4056
pubmed: 28837405
Semin Cancer Biol. 2020 Apr;61:84-100
pubmed: 31521748
Eur Radiol. 2020 Feb;30(2):816-822
pubmed: 31650266
Lancet Reg Health West Pac. 2022 Oct 10;31:100617
pubmed: 36879786